3/21/2014 7:23:40 AM
European regulators have recommended approval of new pills for hepatitis C and diabetes from Johnson & Johnson and Eli Lilly, together with Takeda's injectable drug for bowel disorders. The green light from the European Medicines Agency (EMA) for J&J's Olysio, also known as simeprevir, follows U.S. approval for the hepatitis C treatment in November and adds an important new oral therapy for fighting the liver-destroying disease. Eli Lilly and its partner Boehringer Ingelheim received a recommendation for their diabetes medicine Jardiance, or empagliflozin, which failed to win U.S. approval this month because of manufacturing issues.
Help employers find you! Check out all the jobs and post your resume.
comments powered by